小分子抑制剂抑制Stat3可减缓糖尿病视网膜病变大鼠模型的视力丧失
本研究在链脲佐菌素诱导的Brown Norway糖尿病大鼠模型中,每日口服不同浓度CLT-005(一种Stat3小分子抑制剂)16周,通过视动追踪监测视觉功能。结果显示CLT-005以剂量依赖方式挽救进行性视力丧失,该效应与血管渗漏及视网膜炎症细胞因子改善相关。作者认为Stat3抑制对糖尿病视网膜病变视力丧失具有较强治疗潜力。
要点
- 链脲佐菌素糖尿病大鼠16周内出现进行性视力丧失,CLT-005以剂量依赖方式挽救该视力丧失。
- CLT-005的正向治疗效应与血管渗漏及视网膜炎症细胞因子存在的正向效应相关。
- 作者认为Stat3抑制对糖尿病视网膜病变视力丧失具有较强治疗潜力。
核心结论
- 本研究表明Stat3抑制对糖尿病视网膜病变视力丧失的治疗具有较强潜力。
研究设计与样本
- Brown Norway大鼠经链脲佐菌素诱导糖尿病,自链脲佐菌素给药后4天起每日口服CLT-005,浓度分别为125、250或500 mg/kg,持续16周。
- 采用质谱法量化全身及眼部药物浓度,自6至16周每2周以视动追踪测量视力和对比敏感度,并肉眼监测白内障存在与严重程度并与视力相关分析。
- 通过实时聚合酶链反应和多重组免疫分析测定多种血管生成因子和炎症细胞因子的转录与翻译。
主要发现
- 链脲佐菌素糖尿病大鼠在16周内持续存在进行性视力丧失,CLT-005以剂量依赖方式挽救该视觉功能丧失。
- CLT-005的正向治疗效应与血管渗漏及视网膜炎症细胞因子存在的正向效应相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Diabetic retinopathy is a leading cause of vision loss. Previous studies have shown signaling pathways mediated by Stat3 (signal transducer and activator of transcription 3) play a primary role in diabetic retinopathy progression. This study tested CLT-005, a small molecule inhibitor of Stat3, for its dose-dependent therapeutic effects on vision loss in a rat model of diabetic retinopathy. METHODS: Brown Norway rats were administered streptozotocin (STZ) to induce diabetes. CLT-005 was administered daily by oral gavage for 16 weeks at concentrations of 125, 250, or 500 mg/kg, respectively, beginning 4 days post streptozotocin administration. Systemic and ocular drug concentration was quantified with mass spectrometry. Visual function was monitored at 2-week intervals from 6 to 16 weeks using optokinetic tracking to measure visual acuity and contrast sensitivity. The presence and severity of cataracts was visually monitored and correlated to visual acuity. The transcription and translation of multiple angiogenic factors and inflammatory cytokines were measured by real-time polymerase chain reaction and Multiplex immunoassay. RESULTS: Streptozotocin-diabetic rats sustain progressive vision loss over 16 weeks, and this loss in visual function is rescued in a dose-dependent manner by CLT-005. This positive therapeutic effect correlates to the positive effects of CLT-005 on vascular leakage and the presence of inflammatory cytokines in the retina. CONCLUSIONS: The present study indicates that Stat3 inhibition has strong therapeutic potential for the treatment of vision loss in diabetic retinopathy.
引用
- Vanlandingham PA, Nuno DJ, Quiambao AB, et al. Inhibition of Stat3 by a Small Molecule Inhibitor Slows Vision Loss in a Rat Model of Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2017. PMID: 28395025. doi:10.1167/iovs.16-20641
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。